-
Sector Analysis
Bladder Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Bladder Cancer Pipeline Drugs Analysis Report Overview There are 13 marketed innovator therapies for bladder cancer, with an almost equal number of small molecules and biologics. The Bacillus Calmette-Guerin (BCG) vaccine is considered a gold-standard therapy in high-risk NMIBC (non-muscle-invasive bladder cancer) patients. The bladder cancer marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in bladder cancer therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products...
-
Sector Analysis
Melanoma - Competitive Landscape to 2026
PD-1 targeting immunotherapies are the major focus of drug developers. There are 689 drugs in the pipeline, 47 of which targets PD-1. Big pharma dominates R&D in this indication, with BMS, Roche, Novartis, GSK, Merck & Co. and Pfizer leading the way. Increasing incidence expected to drive the growth in Melanoma market.
-
Sector Analysis
Breast Cancer - Competitive Landscape in 2020
Human epidermal growth factor receptor 2 (HER-2) targeting drugs are the major focus of drug developers. There are 1687 drugs in the pipeline, 319 of which targets HER-2. Big pharma dominates R&D in this indication, with Roche, Novartis, Pfizer, AstraZeneca, and Eli Lilly leading the way. Increasing incidence expected to drive growth in breast cancer market, but patent expiry of several branded therapies poses a threat to the breast cancer space.
-
Sector Analysis
Endometrial Cancer - Epidemiology Forecast to 2030
Endometrial cancer is the most common form of uterine cancer, arising from the endometrial lining of the uterus. Endometroid endometrial cancer is highly associated with increased estrogen levels, making it more common among young women, women with higher levels of body fat, and in those taking a form of exogenous estrogen. In the 8MM, the diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 cases in 2030, at an Annual Growth Rate...
-
Product Insights
Leiomyosarcoma Disease - Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Leiomyosarcoma Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Leiomyosarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Leiomyosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Angioimmunoblastic T-Cell Lymphoma (AITL) Immunoblastic Lymphadenopathy Disease - Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Angioimmunoblastic T-Cell Lymphoma (AITL) Immunoblastic Lymphadenopathy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Angioimmunoblastic T-Cell Lymphoma (AITL) Immunoblastic Lymphadenopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Angioimmunoblastic T-Cell Lymphoma (AITL) Immunoblastic Lymphadenopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 &...
-
Product Insights
Thymoma (Thymic Epithelial Tumor) - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Thymoma (Thymic Epithelial Tumor) - Global Clinical Trials Review, H2, 2021" provides an overview of Thymoma (Thymic Epithelial Tumor) Clinical trials scenario. This report provides top line data relating to the clinical trials on Thymoma (Thymic Epithelial Tumor) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
Sezary Syndrome - Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Sezary Syndrome - Global Clinical Trials Review, H1, 2021" provides an overview of Sezary Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Sezary Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Oligodendroglioma Disease - Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Oligodendroglioma Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Oligodendroglioma Clinical trials scenario. This report provides top line data relating to the clinical trials on Oligodendroglioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Medulloblastoma Disease - Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Medulloblastoma Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Medulloblastoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Medulloblastoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.